Vicore Pharma to Present at Upcoming Investor Conferences

STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 /Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:

• Sweden Life Science Day 2026
  Location: Gothenburg, Sweden
  Format: Presentation
  Presentation Date and Time: Wednesday, March 4 at 9:15 AM CET
  Participant: Hans Jeppsson, CFO

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company 's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO.www.vicorepharma.com

Attachments
Vicore Pharma to Present at Upcoming Investor Conferences

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

© 2026 ACCESS Newswire. All Rights Reserved.